文献速递神经肿瘤

H3.K27me3缺失在CNS WHO 2级脑膜瘤中的预后意义:多中心临床病理研究

Prognostic significance of H3.K27me3 loss in CNS WHO grade 2 meningiomas: a multicentre clinicopathological study.
PubMed 文献 · J Neurooncol · 2026-01-27

该多中心回顾性队列纳入2006至2024年组织学确诊的109例CNS WHO 2级脑膜瘤患者,采用免疫组化检测H3.K27me3并由三位神经病理学家独立评分。结果显示32例(29.4%)存在H3.K27me3缺失,且与较短的无病生存期和总生存期独立相关,提示其可作为术后风险分层的可重复、可及标志物。

要点

  • H3.K27me3缺失见于29.4%的CNS WHO 2级脑膜瘤,与高龄、高核分裂指数和坏死相关。
  • H3.K27me3缺失是无病生存期(aHR=3.314,p=0.001)和总生存期(aHR=3.314,p=0.045)的独立不良预后因素。
  • H3.K27me3评分观察者间一致性较高(κ=0.77),适合常规免疫组化评估。

核心结论

  • H3.K27me3缺失是CNS WHO 2级(不典型)脑膜瘤侵袭性临床行为的可重复、可及且独立的标志物。
  • 常规评估H3.K27me3可能改善术后预后评价并指导辅助治疗管理。

研究设计与样本

  • 多中心回顾性队列研究,纳入2006至2024年组织学确诊的109例CNS WHO 2级脑膜瘤患者。
  • 对代表性肿瘤切片行H3.K27me3免疫组化,由三位神经病理学家独立评估。
  • 采用Fisher精确检验和Mann–Whitney检验分析H3.K27me3状态与临床病理变量的关联。
  • 采用Kaplan–Meier分析、Cox比例风险回归和Aalen-Johansen估计评估无病生存期与总生存期。

主要发现

  • 32例(29.4%)肿瘤检出H3.K27me3缺失,且与年龄较大(p=0.034)、核分裂指数较高(p=0.019)和坏死(p=0.005)显著相关。
  • H3.K27me3评分观察者间一致性为中等偏强(κ=0.77)。
  • 单因素分析中,H3.K27me3缺失(HR=3.243,p<0.001)、次全切除(HR=2.461,p=0.013)和Ki-67>10%(HR=2.136,p=0.026)预测较短无病生存期。
  • 多因素分析证实H3.K27me3缺失(aHR=3.314,p=0.001)和Ki-67>10%(aHR=2.154,p=0.041)为独立预后因素。
  • 总生存期方面,H3.K27me3缺失(aHR=3.314,p=0.045)、年龄≥65岁(aHR=3.721,p=0.007)和脑侵犯(aHR=2.242,p=0.009)为不良预测因素。

关键数值与推荐

  • H3.K27me3缺失定义为免疫组化检测到H3.K27me3表达丢失,具体判读阈值原文未报告。
  • Ki-67>10%作为无病生存期的独立不良预后因素(aHR=2.154,p=0.041)。
  • 年龄≥65岁(aHR=3.721,p=0.007)和脑侵犯(aHR=2.242,p=0.009)为总生存期的不良预测因素。

临床怎么用

  • 对CNS WHO 2级脑膜瘤术后标本可常规行H3.K27me3免疫组化,辅助风险分层。
  • H3.K27me3缺失合并Ki-67>10%提示无病生存期较差,可考虑更密切随访。
  • H3.K27me3缺失、年龄≥65岁或脑侵犯提示总生存期较差,辅助治疗决策时可纳入参考。

局限性

  • 回顾性多中心设计,可能存在选择偏倚。
  • 样本量为109例,H3.K27me3缺失亚组仅32例,统计效能有限。
  • H3.K27me3判读阈值及检测标准化流程原文未明确报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CNS WHO grade 2 meningiomas display heterogeneous biological behaviour, and reliable prognostic markers are needed to refine risk stratification. Loss of histone H3 lysine 27 trimethylation (H3.K27me3) has emerged as a potential immunohistochemical marker of aggressive behaviour, but its prognostic role within CNS WHO grade 2 tumours remains uncertain. METHODS: A retrospective multicentre cohort of 109 patients with histologically confirmed CNS WHO grade 2 meningioma diagnosed between 2006 and 2024 was analysed. Immunohistochemistry for H3.K27me3 was performed on representative tumour sections and independently assessed by three neuropathologists. Associations between H3.K27me3 status and clinicopathological variables were evaluated using Fisher’s exact and Mann–Whitney tests. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan–Meier analysis, Cox proportional hazards regression and Aalen-Johansen estimation. RESULTS: H3.K27me3 loss was detected in 32 (29.4%) tumours and was significantly associated with older age (p = 0.034), higher mitotic index (p = 0.019), and necrosis (p = 0.005). Inter-observer agreement for H3.K27me3 scoring was substantial (κ = 0.77). On univariate analysis, H3.K27me3 loss (HR = 3.243, p < 0.001), subtotal resection (HR = 2.461, p = 0.013), and Ki-67 > 10% (HR = 2.136, p = 0.026) predicted shorter DFS. Multivariate analysis confirmed H3.K27me3 loss (aHR = 3.314, p = 0.001) and Ki-67 > 10% (aHR = 2.154, p = 0.041) as independent prognostic factors. For OS, H3.K27me3 loss (aHR = 3.314, p = 0.045), age ≥ 65 years (aHR = 3.721, p = 0.007), and brain invasion (aHR = 2.242, p = 0.009) were adverse predictors. CONCLUSIONS: H3.K27me3 loss is a reproducible, accessible, and independent marker of aggressive clinical behaviour in atypical meningiomas. Its routine assessment may improve postoperative prognostic evaluation and guide adjuvant management in CNS WHO grade 2 meningiomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nozzoli F, Ortenzi V, Nucci E, et al. Prognostic significance of H3.K27me3 loss in CNS WHO grade 2 meningiomas: a multicentre clinicopathological study. J Neurooncol. 2026. PMID: 41591541. doi:10.1007/s11060-025-05407-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。